Meurot, C.
Martin, C.
Sudre, L.
Breton, J.
Bougault, C.
Rattenbach, R.
Bismuth, K.
Jacques, C.
Berenbaum, F.
Article History
Received: 14 June 2021
Accepted: 11 January 2022
First Online: 28 January 2022
Competing interests
: Dr. Berenbaum reports personal fees from AstraZeneca, Boehringer, Bone Therapeutics, CellProthera, Expanscience, Galapagos, Gilead, Grunenthal, GSK, Eli Lilly, Merck Sereno, MSD, Nordic Pharma, Nordic Bioscience, Novartis, Pfizer, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, 4P Pharma, grants from TRB Chemedica; In addition. Dr Berenbaum is the CEO of 4Moving Biotech and chair of the scientific advisory board of 4P Pharma. Dr. Rattenbach is the CEO of 4P Pharma and the chairwoman of 4Moving Biotech. 4Moving Biotech and Sorbonne University own 2 patents for method of use of GLP1 analogs in the treatment of osteoarthritis (PCT/FR2013/051998 and PCT/IB2018//059100).